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NITmC oxide has been suggested as a contributor
to tissue injury in various experimental models of
gastrointestinal inflammation. However, there is
overwhelming evidence that nitric oxide is one of
the most important mediators of mucosal
defence, influencing such factors as mucus secre-
tion, mucosal blood flow, ulcer repair and the
activity of a variety of mucosal immunocytes.
Nitric oxide has the capacity to down-regulate
inflammatory responses in the gastrointestinal
tract, to scavenge various free radical species and
to protect the mucosa from injury induced by
topical irritants. Moreover, questions can be
raised regarding the evidence purported to
support a role for nitric oxide in producing tissue
injury. In this review, we provide an overview of
the evidence supporting a role for nitric oxide in
protecting the gastrointestinal tract from injury.
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Introduction
It is now widely accepted that nitric oxide
(NO) synthesized from -arginine is the sub-
stance that accounts for the activity originally
described by Furchgott and Zawadzki as ’endo-
thelium-derived relaxing factor’. Nitric oxide is
produced by virtually all mammalian cells. In the
intestine, nitric oxide is produced by three dis-
tinct enzyme systems, referred to as nitric oxide
synthases (NOS). A neurally associated, con-
stitutive form of NOS found in neurons of the
enteric nervous system is referred to as NOS1 or
ncNOS. An inducible form of the enzyme, refer-
red to as NOS2 or iNOS, is found under appro-
priate circumstances in endothelial cells, the
epithelium and in a number of immunocytes.
This enzyme can be induced by exposure to
various cytokines and endotoxin. NOS3 (or
ecNOS) is a constitutively expressed enzyme
found primarily in the endothelium lining blood
vessels, but may also exist in intestinal epithelial
cells and mast cells. One of the important distin-
guishing features between the constitutive and
inducible forms of NOS is the calcium-depen-
dency of the former but not the latter. For the
most part, NOS1 and NOS3 can be regarded as
the forms that are responsible for producing
nitric oxide in a physiological context, whereas
NOS2 produces nitric oxide in pathophysiologi-
cal circumstances. However, this statement
should not be construed as meaning nitric oxide
derived from NOS2 only acts in a detrimental
manner.
In recent years, a plethora of studies have
implicated NO as a critical mediator of mucosal
defence in the gastrointestinal tract. On the other
hand, it has been suggested by many groups that
nitric oxide contributes to mucosal injury in
several human gastrointestinal disorders and in
experimental animal models of gastrointestinal
injury. Like oxygen, high concentrations of NO
oxide are cytotoxic. While there are considerable
data suggesting that NO production is greatly ele-
vated in situations of mucosal inflammation, such
as in inflammatory bowel disease, it has yet to be
clearly established that NO plays a primarily
damaging role in those circumstances, or that it
ever accumulates to concentrations that could
achieve such results.
In this review, we summarize some of the key
evidence suggesting a role for nitric oxide in the
maintenance of gastrointestinal mucosal integrity,
and we challenge the hypothesis that nitric oxide,
when present in ’large’ amounts, necessarily
results in mucosal injury and dysfunction.
Nitric oxide and mucosal defence
The mucosa of the gastrointestinal tract is con-
tinuously exposed to potentially damaging sub-
stances, such as acid, digestive enzymes, bacterial
toxins and bile. The ability of the mucosa of the
gastrointestinal tract to resist injury by these sub-
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Table 1. Effects of inhibition of nitric oxide synthase or administration of nitric oxide donors in models of gastrointestinal injury
Model of injury Inhibition of nitric oxide synthase Exogenous nitric oxide administration
Hydrochloric acid
Ethanol
NSAIDs
Platelet-activating factor
Endothelin-1
Ischaemia-reperfusion
Stress
Endotoxin
Exacerbates gastric lesions
3
Exacerbates gastric damage
Exacerbates gastric lesions19
Exacerbates intestinal lesions
56
Elevated protein accumulation in lumen
of stomach and duodenum
8
Elevated mucosal and vascular permeability81’82
Increased ulcer severity
84 and mucosal
permeability
85
Increased luminal albumin leakage and mucosal
injury
86
Prevents gastric lesions
3
Prevents gastric damage2"5
Reduces severity of gastric and intestinal
damage7,8.19,79
Reduces mucosal permeability; reduces severity
of intestinal lesions
56
Reduces severity of gastric lesions
8
Reduced mucosal permeability;
82 reduced gastric
lesions;
54 improved survival
83
Not tested
Reduced gastric and intestinal injury87"88
stances is attributable to a complex and dynamic
network of factors collectively referred to as
’mucosal defence’. This includes extracellular
factors, such as mucus, which helps to prevent
abrasive injuey to the mucosa and to impair
attachment of microbes to the epithelium. The
epithelium of the gastrointestinal tract itself
forms an important barrier, restricting the move-
ment of large molecules into the mucosa and
secreting fluid into the lumen in order to wash
away potentially harmful microbes or toxins. The
subepithelium is richly inneeeated by both the
extrinsic and enteric nervous systems, which are
capable of triggering changes in several of the
components of the mucosal defence network
when damage to the epithelium is detected or if
toxins enter the lamina propria in sufficient
quantities. One of the most rapid and important
mucosal defence responses is an increase in
mucosal blood flow, which acts to dilute the
toxic substances, neutralize them and remove
them from the tissue before they can accumulate
to damaging concentrations. This has been parti-
cularly well characterized in the stomach, where
back-diffusing acid can trigger sensory afferent
neurons beneath the epithelium. The subsequent
release of calcitonin gene-related peptide in the
vicinity of the submucosal arterioles results in a
rapid and profound increase in mucosal blood
flow, thereby effectively neutralizing the back-
diffusing acid that had triggered the response.
The various components of mucosal defence
are co-ordinated and modulated via the release
of a number of soluble mediators. For example,
prostaglandins play a very important role in the
maintenance of mucosal integrity, stimulating vir-
tually every component of the mucosal defence
network. Over the past 10 years, substantial data
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have been generated to suggest that nitric oxide
is another key mediator of mucosal defence in
the gastrointestinal tract.
Nitric oxide can protect the GI tract
MacNaughton et al.
2 demonstrated that nitric
oxide itself or an NO donor could protect the
gastric mucosa from damage induced by topically
applied ethanol. Moreover, administration of the
guanylate cyclase inhibitor, methylene blue, or
the nitric oxide scavenger, oxyhaemoglobin, pre-
vented the protective effects of exogenous NO
and increased the susceptibility of the gastric
mucosa to injury. These findings have now been
extended by Kitagawa et al., who showed pro-
tective effects of nitric oxide donors in an acid-
induced model of damage in the rat, by Lopez-
Belmonte et al.4 who demonstrated that nitric
oxide donors reduced the severity of ethanol-
induced damage, and by Masuda et al.5 who
demonstrated that blockade of nitric oxide synth-
esis greatly increased the susceptibility of the
stomach to damage induced by ethanol, a
summary of the studies implicating nitric oxide
in gastrointestinal mucosal resistance to injury is
provided in Table 1.
The ability of nitric oxide to reduce the sever-
ity of damage induced bynonsteroidal anti-
inflammatory drugs (NSAIDs) has recently been
exploited in an attempt to produce NSAIDs
which are not ulcerogenic. By attaching a nitric
oxide releasing moiety to standard NSAIDs, the
ulcerogenic effects of these compounds was
greatly reduced without adversely affecting their
68 anti-inflammatory properties. These com-
pounds appear to release nitric oxide very slowly
and in small amounts. Thus, the compounds doNitric oxide and mucosal defence
not affect systemic arterial blood pressure, but mucosa is exposed to an irritant. Blockade of
the release of NO is sufficient to maintain gastric this response, by ablation of sensory afferent
mucosal blood flow and prevent leukocyte neurons, renders the mucosa unable to withstand
adherence to post-capillary venules.7’u Decreased even brief exposure to topical irritants such as
mucosal blood flow and leukocyte adherence are 15% ethanol.4The reactive hyperaemic response
obseeeed with standard NSAIDs and are believed is a nitric oxide-dependent response. Calcitonin
to contribute to the pathogenesis of NSAID- gene-related peptide accounts for the largest
induced gastropathy.9 component of the gastric reactive hyperaemic
There is also recent evidence to suggest that response,
15 and its effects on vascular smooth
endogenous nitric oxide derived from the induci- muscle tone are mediated through the genera-
ble isoform of nitric oxide synthase (NOS2) is tion, presumably by the vascular endothelium, of
capable of protecting the stomach, which flies in nitric oxide. Prior treatment of rats with inhibi-
the face of claims that the large amounts of nitric tors of nitric oxide synthase abolishes the reac-
oxide produced via this enzyme will cause tissue rive hyperaemic response to topical irritants and
injury. Tepperman and Soper demonstrated greatly increases the susceptibility of the stomach
that administration of endotoxin to rats led to a to damage.
significant increase in NOS2 activity within the Nitric oxide also plays a key role in modulating
gastric mucosa. When the stomach was chal- basal gastric blood flow, since it can be reduced
lenged by intragastric administration of ethanol, by administration of NOS inhibitors.7 Moreover,
the rats previously given endotoxin were found this reduction of mucosal blood flow by NOS
to be significantly more resistant to damage. That inhibitors probably underlies their ability to
this protection was mediated via nitric oxide was increase the susceptibility of the gastric mucosa
supported by their observation that administra- to iniury induced by various topical irritants, such
tion of L-NAME (a non-selective NOS inhibitor) as ethanol and NSAIDs.4’18’19
or dexamethasone inhibited the protective effects
associated with endotoxin treatment. In the case
of dexamethasone, they demonstrated a selective
inhibition of the inducible nitric oxide synthase
within the gastric mucosa.
Nitric oxide modulates mucus secretion
Nitric oxide is important in repair of
mucosal injury
Repair of gastrointestinal injury can be sub-
divided into two major types. When damage is
limited to the most superficial layers of cells,
rapid repair of the epithelium is possible through
Mucus secretion by the epithelium is believed the process of restitution. This involves migration
to form one of the primary levels of mucosal of healthy cells from the uninjured margins, over
defence against acid in the stomach and duode- the exposed basement membrane,
g The restitu-
num. Mucus also plays a key role in preventing tion process in vivo is dependent upon the
abrasive injury to the gut epithelium, in limiting maintenance, in the region of injury, of a micro-
the access of luminal bacteria to the epithelial environment of near neutral pH (the basement
surface and as an anti-oxidant. Bicarbonate is membrane is very susceptible to damage by acid
produced in small amounts relative to the and restitution will not occur if the basement
amount of acid produced by the stomach, but membrane is damaged).
21 Mucosal hyperaemia
when trapped within mucus on the surface of and the leakage of plasma at the site of injury is
the epithelium can form a pH gradient. Nitric responsible for maintaining the neutral pH
oxide appears to be one of the most important microenvironment. Takeuchi et a/.22 recently
signals for mucus secretion. Brown et al.
2 demonstrated that blockade of nitric oxide pro-
demonstrated that nitric oxide donors and a duction results in an impairment of the vascular
cGMP analogue could stimulate mucus release, response and the consequent alkaline flux into
Furthermore, Price et al. reported that nitric the lumen and in turn, to an impairment of the
oxide was the mediator responsible for choliner- restitution process.
gic-stimulated mucus release. The second major type of repair that occurs in
the gastrointestinal tract is that associated with
injury that involves the full thickness of the
Nitric oxide mediates mucosal mucosa, and perhaps even the submucosa and
muscularis (i.e. true ulcers). This process hyperaemic responses involves the formation of granulation tissue at the
As outlined above, a very important compo- ulcer base, the process of angiogenesis and the
nent of mucosal defence is the elevation of subsequent re-establishment of glandular struc-
mucosal blood flow that occurs when the ture (this occurs primarily from the margins of
Mediators of Inflammation Vol 4 1995 399P. Kubes and J. L. Wallace
the ulcer). While the mechanisms of action are the capacity to produce nitric oxide, and could
yet to be determined, there is now clear evidence therefore modulate epithelial permeability. There
that nitric oxide can accelerate this healing is now strong evidence for mast cells exerting
process. Konturek et a/.23 first demonstrated that such control through the release of nitric oxide
administration of a nitric oxide donor (glyceryl (see below).
trinitrate) significantly accelerated the healing of
gastric ulcers in the rat. They also showed that Nitric oxide modulates the mucosal administration of an inhibitor of nitric oxide immune system synthesis impaired ulcer healing. These results
were recently confirmed by Elliott et al.
24 who The mucosal immune system plays an essential
showed that oral but not intraperitoneal glyceryl role in protecting us from the enormous quan-
trinitrate accelerated ulcer healing in the rat. tities of microbes, microbial products and other
Moreover, administration of a nitric oxide-releas- antigens present in the lumen of the gut. The
ing NSAID derivative, but not the parent NSAID, normal gut could be said to be in a state of
significantly accelerated ulcer healing.
24 ’controlled inflammation’. While there is a con-
stant exposure of the gut to substances that
Nitric oxide regulates intestinal mucosal could stimulate an immune response, which
barrier function could lead to inappropriate injury to the host
tissue, a number of mediators act to keep the
Inhibition of nitric oxide synthase results, inflammatory response in check. Included among
within minutes, in a substantial increase in small these down-regulatory molecules are interleukin-
intestinal epithelial permeability. For example, 10, prostaglandins and nitric oxide.
the transepithelial movement of a marker such as The ability of nitric Oxide to down-regulate
5Cr-EDTA is greatly enhanced following adminis- immunocyte function has been demonstrated in
tration of the NO synthase inhibitor L-NAME.25 a number of cell systems. For example, macro-
This increase in epithelial permeability can also phage-derived NO has been suggested to sup-
be induced by other inhibitors of nitric oxide press the proliferation of T lymphocytes and to
synthesis, and can be reversed by nitric oxide mediate several aspects of macrophage func-
donors, -arginine or cGMP analogues. On the tion. As outlined below, nitric oxide is a potent
other hand, administration of biologically inactive suppressor of neutrophil function, inhibiting
enantiomers of the NO synthase inhibitors had both adherence and activation. With respect to
no effect on epithelial permeability. This role for the gastrointestinal tract, perhaps the best char-
nitric oxide in the intestine has now been acterized immunoregulatory effect of nitric oxide
demonstrated in the cat,
25 guinea-pig
2 and rat.2v is its ability to inhibit mediator release from mast
It is important to note that in the studies cells. Salvemini et al. first reported the ability of
described above, inhibition of nitric oxide synth- exogenous nitric oxide to inhibit release of hista-
esis did not result in widespread disruption of mine from peritoneal mast cells. These studies
the epithelium. Indeed, the permeability of the were later extended by Masini et al.,
32 who
epithelium to molecules such as albumin (MW demonstrated that mast cells could produce
60 000), was not affected by the inhibitors of NO nitric oxide, and by Hogaboam et aL, who
synthase. Moreover, the effect of NO synthase reported that the nitric oxide produced by the
inhibition on permeability to EDTA was very mast cell autoregulated the release of other
rapidly reversed by administration of an NO inflammatory mediators, such as platelet-activat-
donor, demonstrating that the permeability ing factor (PAF). The ability of the mast cell to
change was not due to damage of the epithelium produce nitric oxide could be greatly enhanced
or to the tight junctions. As epithelial cells in the by very brief exposure to interleukin-1. Nitric
gastrointestinal tract have the capacity to produce oxide release from mast cells also contributes to
nitric oxide,
28 it is possible that these cells can the ability of these cells to kill target tumour
exert autoregulation of their own permeability, cells.4
The factors that increase or decrease nitric oxide These in vitro studies of mast cells have now
production by the epithelium have not yet been been extended to in vivo models. Kanwar et
well characterized, although it is interesting to a/.27 demonstrated that administration of a nitric
note that the reduction of epithelial permeability oxide synthase inhibitor resulted in a marked
that can be induced by interferon-gamma was increase in serum levels of a protease specific to
recently shown to be mediated via the produc- mucosal mast cells. Using histochemical
tion of nitric oxide.29 Of course, numerous other methods, degranulation of connective tissue-type
cells in the lamina propria, including enteric mast cells in the mesentery was also demon-
neurons, mast cells and macrophages, also have strated.5 Associated with the degranulation of
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mast cells was a rapid increase in permeability of Nitric oxide inhibits neutrophil adherence
the intestinal epithelium to the small molecular and activation
weight marker, EDTA.
2v The permeability
changes observed could be prevented by pre- Neutrophils are a major contributor to gastro-
treating the rats with various mast cell stabilizers intestinal injury, including that associated with
or with receptor antagonists to PAF or the hista- inflammatory bowel disease42 and Helicobacter
mine H-1 receptor. Taken together, these studies pylori-associated ulcer disease.43’44 Moreover, a
demonstrate that inhibition of nitric oxide synth- key role for neutrophils as effectors of tissue
esis leads to mast cell degranulation. The release damage has been demonstrated in various
of mediators such as histamine and PAF results experimental models of intestinal injury and
in increases in intestinal epithelial permeability, inflammation, including that induced by ischae-
In addition, inhibition of nitric oxide synthesis mia-reperfusion,45’4 PAF,47 indomethacin48-5
led to increased numbers of leukocvtes adhering and ethanol.51’52 The evidence for a role for neu-
36 to mesenteric post-capillary venules. This effect, trophils in these models includes the observa-
which is discussed in more detail below, also tions that: (1)neutrophils infiltrate the inflamed
appeared to be mast cell-dependent.
5 tissue; (2) rendering animals neutropenic
Similar findings have been reported by Kurose reduces tissue injury; and (3) antibodies against
et al.,r who studied the effects of ischaemia- neutrophil and/or endothelial adhesion mole-
reperfusion on intestinal mast cells. They visually cules reduce the extent of injury.
assessed mast cell integrity after 30 min of reper- Nitric oxide has been suggested as an impor-
fusion of ischaemic mesentery and noted a sig- rant modulator of neutrophil adherence to the
nificant increase in degranulated mast cells that vascular endothelium. Inhibition of nitric oxide
was entirely inhibited by nitric oxide donors, synthesis leads to elevated numbers of neu-
They also demonstrated that endogenous nitric trophils adhering to walls of vessels.5 As out-
oxide was reduced by 90% following the period lined above, this may be in part a mast cell-
of ischaemia, while supplementation of the tissue dependent phenomenon. Based on these obser-
with nitric oxide donors significantly reduced vations, it has been suggested that one of the
leukocyte infiltration and microvascular dysfunc- mechanisms through which nitric oxide can
tion. The authors concluded that the reduction in reduce injury in the gastrointestinal tract is
nitric oxide production associated with ischae- through inhibition of neutrophil recruitment to
mia-reperfusion led to destabilization of mast the tissue. Indeed, in numerous studies, adminis-
cells, as a consequence of reduced nitric oxide tration of nitric oxide donors reduced gastro-
production, and the subsequent release of pro- intestinal myeloperoxidase activity (an index of
adhesive molecules such as histamine, PAF and tissue granulocyte numbers) as well as reducing
leukotrienes. It is these mediators which ulti- tissue injury. Andrews eta/.54 demonstrated that
mately elicited the inflammatory response, fewer neutrophils infiltrated the post-ischaemic
Although the platelet is generally viewed in the gastric mucosa following nitroprusside or acet-
context of its important role in thrombosis and ylcholine administration and this regimen of
coagulation, there is considerable evidence that nitric oxide generators protected the reperfused
platelets also contribute significantly to inflam- tissue. Kurose et aL55 demonstrated that adminis-
matory processes.
8 Nitric oxide is a very potent tration of nitric oxide donors resulted in a
inhibitor of platelet aggregation and adherence,9 marked attenuation of leukocyte adhesion and
and may therefore exert anti-inflammatory effects emigration, as well as vascular dysfunction in the
by suppressing platelet activation. Nishida et al.4 post-ischaemic mesentery. Mackendrick et al.56
recently reported that suppression of nitric demonstrated that inhibition of nitric oxide pro-
oxide synthesis during administration of endo- duction resulted in an exacerbation of PAF-
toxin profoundly increased platelet and fibrin induced neutrophil influx into the mucosa as
deposition in liver sinusoids. They suggested that well as an increase in tissue injury. As mentioned
inhibition of endogenous nitric oxide results in above, the addition of a nitric oxide-releasing
platelet aggregation which contributes to plug- moiety to standard NSAIDs resulted in prevention
ging of the sinusoids and tissue injury. Har- of the neutrophil adherence to mesenteric post-
brecht et al.
4 also suggested an important role capillar venules normally seen with the parent
for inducible NOS in preventing thrombus for- NSAID.
mation in situations of endotoxaemia. They It should be noted that prevention of infiltra-
found that suppression of NO synthesis in endo- tion of circulating neutrophils into the intestine
toxaemic animals led to intrahepatic thrombus may not fully explain the protective effects of
formation and oxygen radical-mediated liver nitric oxide. For example, in experimental
damage, ischaemia-reperfusion-induced injury, circulating
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neutrophils appear to contribute significantly to influx) and both superoxide dismutase and NO
the microvascular but not the mucosal dysfunc- donors directly inhibited this response, further
tion.5 This is based on the fact that pretreatment suggesting a lotential anti-oxidant ability of these
with an anti-CD18 antibody, which prevents leu- NO donors. Finally, Wink et al.69 recently pro-
kocyte adhesion to post-capillary venules, sig- posed a protective role for NO donors in cellular
nificantly attenuated the increase in microvascular injury induced by hydrogen peroxide. Since cata-
permeability but did not affect the rise in lase, which is a hydrogen peroxide-detoxiTin
mucosal permeability.
5v On the other hand, nitric agent, can also reduce intestinal inflammation,
oxide donors have been shown to reduce both the possibility that NO donors counter both
microvascular and mucosal injury in the intestine, superoxide and hydrogen peroxide-induced
Since adhering neutrophils do not mediate the tissue injury cannot be excluded.
mucosal permeability alterations in reperfused
intestine, then nitric oxide must have other bene- Large amounts of nitric oxide do not ficial effects in addition to its anti-adhesive prop- cause intestinal injury erties. One possibility is that nitric oxide can
inhibit functions of neutrophils other than their It has repeatedly been suggested that produc-
ability to adhere to the vascular endothelium. For tion of ’large’ amounts of nitric oxide, such as
example, nitric oxide may directly inactivate the may occur when the inducible form of NOS is
enzyme responsible for the oxidative burst that is present, will result in damage within the gastro-
generated by activated neutrophils. Clancy et al.58 intestinal tract or, indeed, in other tissues. In an
have demonstrated that nitric oxide can inhibit attempt to test this hypothesis, in vivo and in
superoxide production from neutrophils by vitro studies on the feline intestine and human
directly inhibiting NADPH oxidase. Therefore, in epithelial cells, respectively, were performed
addition to scavenging superoxide (discussed which involved local infusion of high concentra-
below), nitric oxide can prevent the synthesis of tions of nitric oxide donors (CAS 754 or SIN-l)
superoxide and associated oxidants including into autoperfused segments of cat ileum.
7 Rather
hydrogen peroxide. Thus, in addition to prevent- than looking for overt tissue damage, very subtle
ing leukocyte adhesion and infiltration into the functional alterations were used as indices of
reperfused intestine, nitric oxide may also intestinal dysfunction. These included measure-
directly affect the cytotoxicity of neutrophils by ments of both microvascular and mucosal per-
altering the ability of this cell to produce oxi- meability. These studies clearly demonstrated that
dants. Other inhibitory effects of nitric oxide local infusion of compounds that would release
donors on neutrophil function have also been ’large’ amounts of NO failed to cause changes in
reported.59- microvascular permeability, changes in the integ-
rity of the mucosal barrier or impairment in the
Nitric oxide is an anti-oxidant functional aspects (absorption or secretion) of
the small bowel. Furthermore, when these NO
In addition to being anti-adhesive, nitric oxide donors were added to endothelial or epithelial
has the capacity to inhibit reactive oxygen meta- cells in vitro, they failed to produce detectable
bolites, including superoxide anion, and can damage. This is in sharp contrast to the pro-
prevent the cellular damage attributable to found injury (i.e. lysis) observed when a hypox-
hydrogen peroxide.2’ Both superoxide and anthine/xanthine oxidase system, which
hydrogen peroxide have been implicated in the generates superoxide anions, was added to the
mucosal injury associated with ischaemia-reler- cultured cells. Similar observations have been
fusion64 and the administration of ethanol5-v or reported by others. For example, nitric oxide
NSAIDs.68 Nitric oxide may play a role in redu- released from DEA/NO or spermine-NO them-
cing the injury in these models through its ability selves did not cause cytotoxicity and in fact pre-
to inactivate oxidants. Indeed, nitric oxide has vented cellular injury to Chinese hamster lung
been shown to rapidly react with sup.eroxide to fibroblasts or rat mesencephalic dopaminergic
62 abolish its biological activity in vitro. There is cells induced by either hydrogen peroxide or
also evidence suggesting that this occurs in vivo, superoxide.9 These data raise some questions
since the anti-oxidant capacity of plasma was about the contention that nitric oxide per se
doubled by administration of nitric oxide donors directly injures cells of the intestine or other
at concentrations that lrevented reperfusion- organs.
63 r induced mucosal injury. Othe in v,vo expert- It might be argued that large amounts of nitric
ments demonstrated that administration of a oxide may only produce tissue injury if released
superoxide-generating system could induce at in a setting of active inflammation. In an attempt
least one feature of inflammation (neutrophil to test this hypothesis, further experiments using
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an autoperfused segment of cat intestine were derived from a reaction dependent on nitric
performed, but in addition to administering nitric oxide synthesis.2 This evidence supports the
oxide donors, the pro-inflammatory mediator concept that peroxynitrite is formed under con-
PAF was infused,v By itself, PAF caused a pro- ditions of intestinal inflammation, but does not
found increase in both mucosal and micro- address whether or not it contributes to the
vascular permeability. Concomitant administration tissue injury. Blockade of nitric oxide synthase
of the nitric oxide donor, CAS 754, did not with L-NAME has been shown to reduce the
augment these permeability changes; in fact, the severity of experimental colitisv5 and experi-
nitric oxide donor inhibited the permeability mental ileitis.2< Administration of aminoguani-
enhancing effects of PAF. dine, which is a more selective inhibitor for
inducible NOS, produced an even more impress-
What about peroxynitrite?
ive reduction of injury and inflammation.
7 While
these data support a role for nitric oxide in pro-
Nitric oxide is often described as being highly ducing tissue injury and inflammation, they do
reactive and a gas. In biological settings, not directly address the role of peroxynitrite.
however, it is neither,v Nitric oxide reacts very There is also evidence that intracolonic adminis-
slowly with most biological molecules and there- tration of peroxynitrite will cause extensive
fore its proposed cytotoxicity is dependent upon damage and inflammation in the rat.
v8 Again,
conversion to much more reactive oxidants. In however, this does not address the issue of
fact, much of the apparent cytotoxicity of nitric whether or not endogenous peroxynitrite pro-
oxide has been attributed to its reaction with duction contributes to tissue injury in colitis. It is
superoxide anion to form peroxynitrite]
2 Perox- clear that real progress in answering this ques-
ynitrite is itself cytotoxic, and it can rapidly tion will be dependent upon the development of
decompose to the highly reactive and toxic highly selective inhibitors of the inducible
hydroxyl radical (OH.) and nitrogen dioxide isoform of NOS, and improved methods for
(NO2 o).-71 The tissue damage that can be caused detecting the production of peroxynitrite in viva
by peroxynitrite is attributable to its ability to Finally, some caution should be exercised
oxidize sulfhydryl groups within cells, thereby when interpreting the results from studies in
depleting an important scavenging mechanism, which >NAME is chronically administered and
This leads to increased susceptibility of the cell found to reduce the severity of experimental
to oxidant-induced damage to membrane lipids intestinal inflammation. While it is possible that
and proteins, various enzymes and DNA.73 this effect of L-NAME is attributable to suppres-
There are a couple of points that should be sion of nitric oxide synthesis, and indicative of
considered with respect to the putative role of NO playing a role in the production of tissue
peroxynitrite in intestinal injury. Rubbo et a/.74 injury, there are other possible explanations.
recently reported that NO actually inhibits perox- First, t-NAME is capable of reducing blood flow
ynitrite-induced lipid peroxidation. While NO to tissues, and in doing so, may reduce the influx
could participate in the generation of peroxyni- of granulocytes. Secondly, t-NAME may cause
trite, by reacting with superoxide anion, and had leukocyte adhesion in tissues other than the one
the capacity to cause lipid peroxidation, this only being studied, therefore resulting in an apparent
occurred when the concentrations of NO and decrease in infiltration of these inflammatory
superoxide anion present were equal. When NO cells into the intestine. Thirdly, in light of the
concentrations were increased, as may well be observed ability of L-NAME to cause degranula-
27 the case in situations of inflammation, NO inhib- tion of mast cells in the gastrointestinal tract,
ited peroxynitrite-dependent lipid peroxidation, one must consider the possibility that with
What evidence is there supporting a role for chronic administration of this compound there
peroxynitrite in the production of gastrointestinal could be a progressive depletion of inflammatory
injury? A problem with attempting to provide mediators from these cells. It is therefore possi-
such evidence is the lack of a selective inhibitor ble that such a depletion could contribute to the
of the formation or actions of this substance. It beneficial effects of L-NAME administration over a
is possible to stain tissues for the presence of prolonged period of time. Finally, virtually all the
nitrotyrosine, a product produced when perox- experimental models of intestinal inflammation
ynitrite reacts with tyrosine residues in a tissue.
71 are dependent upon the presence within the gut
Miller et a/.26 demonstrated positive staining for lumen of microbes. It is entirely possible that
nitrotyrosine in inflamed ileum of guinea-pig. The chronic L-NAME administration alters the nature
fact that inhibition of nitric oxide synthase resul- and/or numbers of microbes within the gut
ted in diminished staining for these products lumen and in doing so, alters the magnitude of
supports the concept that the nitrotyrosine was the mucosal inflammatory response. These alter-
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native explanations for the beneficial effects of
chronic t-NAME administration in experimental
models of gastrointestinal inflammation have yet
to be systematically evaluated.
Conclusions
There can be little doubt that nitric oxide is
among the most important mediators of gastro-
intestinal rnucosal defence, influencing virtually
every component of the mucosal defence
network. There is emerging evidence that NO is
an important endogenous scavenger of various
free radical species, and that suppression of NO
synthesis can lead to oxidant-mediated tissue
injury. More controversial is the putative role of
NO, when produced in ’large’ amounts via the
inducible isoform of NOS, in the production of
gastrointestinal injury. While there is evidence
that chronic suppression of NO synthesis can
reduce some indices of tissue injury and inflam-
mation in experimental models, these effects may
not be due to inhibition of the production of
cytotoxic concentrations of NO. Indeed, there is
convincing evidence that administration of large
amounts of NO does not cause detectable
damage to the mucosa or vasculature of the
intestine. There is also recent in vitro data which
raise questions about the role of peroxynitfite in
the production of tissue injury; specifically,
whether conditions ever exist, physiologically or
pathophysiologically, in which this substance
would be produced in sufficient quantities to
cause significant injury. In our view, the vast
majority of available data point to nitric oxide
serving a critical role in protecting the gastro-
intestinal mucosa from injury induced by reactive
oxygen metabolites and other cytotoxic sub-
stances.
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